Premium
Long‐Term Treatment with Oral Sustained‐Release Theophylline
Author(s) -
Bundgaard Allan,
Weeke Bent
Publication year - 1982
Publication title -
allergy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.363
H-Index - 173
eISSN - 1398-9995
pISSN - 0105-4538
DOI - 10.1111/j.1398-9995.1982.tb01890.x
Subject(s) - theophylline , placebo , asthma , medicine , bronchodilator , anesthesia , therapeutic index , pharmacology , drug , alternative medicine , pathology
The treatment of chronic asthma with a sustained‐release rheophylline preparation was evaluated in a placebo controlled, 2 × 4 week, randomised, double‐blind study. The dose which would give serum theophylline levels in the range of 10–20 meg/ml had been previously determined for each patient. This individualization of dosage resulted in 80% of the patients having scrum content rations within the 10–20 meg/ml therapeutic range. The average daily close taken by males was 998.55 mg (range 700–1175 mg) and by females 778.1 (range 500–1000 mg). Of the 33 patients who completed the study 28 had less asthma during the theophylline period, lour did not respond and one did better during the placebo period. No serious side effects were reported. During theophylline therapy. patient's requirements for aerosol bronchodilators were significantly reduced.